Abstract
Background Cognitive decline remains highly underdiagnosed despite efforts to find novel biomarkers for detection. EEG biomarkers based on machine learning may offer a noninvasive low-coast approach for identifying cognitive decline. However, most studies use multi-electrode systems which are less accessible. This study aims to evaluate the ability to extract cognitive decline biomarkers using a wearable single-channel EEG system with an interactive assessment tool.
Methods This pilot study included data collection from 82 participants who performed a cognitive assessment while being recorded with a single-channel EEG system. Seniors in different clinical stages of cognitive decline (healthy to mild dementia) and young healthy participants were included. Seniors’ MMSE scores were used to allocate groups with cutoff scores of 24 and 27. Data analysis included correlation analysis as well as linear mixed model analysis with several EEG variables including frequency bands and three novel cognitive biomarkers previously extracted from a different dataset.
Results MMSE scores correlated significantly with reaction times, as well as two EEG biomarkers: A0 and ST4. Both biomarkers showed significant separation between study groups: ST4 separated between the healthy senior group and the low-MMSE group. A0 differentiated between the healthy senior group and the other three groups, showing different cognitive patterns between different stages of cognitive decline as well as different patterns between young and senior healthy participants. In the healthy young group, activity of Theta, Delta and VC9 biomarker significantly separated between high cognitive load and resting state. VC9 and Theta showed a finer separation between high and low cognitive load levels consistent with previous reports.
Conclusions This study successfully demonstrated the ability to assess cognitive state with an easy-to-use single-channel portable EEG device and a short interactive cognitive assessment. Future studies should explore potential usefulness in controlled studies characterizing changes in EEG patterns of cognitive decline over time, for detection of cognitive decline in every clinic to potentially allow early intervention.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04386902
Funding Statement
No external funding was received for this study. The equipment was provided by Neurosteer Inc. as part of the trial.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was granted by the Ethics Committee (EC) of Dorot Geriatric Medical Center.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data analysis section updated with LMM analysis; Results and discussion updated accordingly. Figure 5-6 revised; Tables 5-7 revised.
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to restrictions (containing information that could compromise the privacy of research participants).
